Loading...
United Therapeutics Corporation
UTHR•NASDAQ
HealthcareBiotechnology
$319.96
$-4.01(-1.24%)
United Therapeutics Corporation (UTHR) Financial Performance & Statements
Review United Therapeutics Corporation’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
23.63%
↑ 23.63%
Operating Income Growth
16.21%
↑ 16.21%
Net Income Growth
21.35%
↑ 21.35%
Operating Cash Flow Growth
35.70%
↑ 35.70%
Operating Margin
46.88%
↑ 46.88%
Gross Margin
89.002%
↑ 89.002%
Net Profit Margin
40.44%
↑ 40.44%
ROE
19.33%
↑ 19.33%
ROIC
19.99%
↑ 19.99%
United Therapeutics Corporation (UTHR) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for United Therapeutics Corporation stock.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $794.40M | $735.90M | $748.90M | $714.90M |
| Cost of Revenue | $92.50M | $75.90M | $83.10M | $77.80M |
| Gross Profit | $701.90M | $660.00M | $665.80M | $637.10M |
| Gross Profit Ratio | $0.88 | $0.90 | $0.89 | $0.89 |
| R&D Expenses | $149.00M | $133.80M | $103.50M | $139.60M |
| SG&A Expenses | $170.10M | $162.50M | $219.20M | $177.60M |
| Operating Expenses | $319.10M | $302.30M | $322.70M | $317.20M |
| Total Costs & Expenses | $411.60M | $378.20M | $405.80M | $395.00M |
| Interest Income | $51.10M | $49.30M | $49.80M | $46.20M |
| Interest Expense | -$6.10M | $7.90M | $10.10M | $11.60M |
| Depreciation & Amortization | $0.00 | $19.70M | $19.10M | $18.70M |
| EBITDA | $382.80M | $424.10M | $417.80M | $338.60M |
| EBITDA Ratio | $0.48 | $0.58 | $0.56 | $0.47 |
| Operating Income | $382.80M | $357.70M | $343.10M | $319.90M |
| Operating Income Ratio | $0.48 | $0.49 | $0.46 | $0.45 |
| Other Income/Expenses (Net) | $40.70M | $38.80M | $45.50M | $35.40M |
| Income Before Tax | $423.50M | $396.50M | $388.60M | $355.30M |
| Income Before Tax Ratio | $0.53 | $0.54 | $0.52 | $0.50 |
| Income Tax Expense | -$101.30M | $95.20M | $79.50M | $77.20M |
| Net Income | $322.20M | $301.30M | $309.10M | $278.10M |
| Net Income Ratio | $0.41 | $0.41 | $0.41 | $0.39 |
| EPS | $7.18 | $6.74 | $6.93 | $6.26 |
| Diluted EPS | $6.63 | $6.19 | $6.39 | $5.85 |
| Weighted Avg Shares Outstanding | $44.90M | $45.20M | $44.60M | $44.40M |
| Weighted Avg Shares Outstanding (Diluted) | $48.60M | $48.70M | $48.40M | $47.50M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan